Share on StockTwits

Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating restated by stock analysts at TheStreet in a report issued on Friday, reports.

The analysts wrote, “Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”

Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.07% during mid-day trading on Friday, hitting $80.65. 10,830,599 shares of the company’s stock traded hands. Gilead Sciences has a one year low of $39.48 and a one year high of $84.40. The stock has a 50-day moving average of $75.92 and a 200-day moving average of $67.27. The company has a market cap of $123.7 billion and a price-to-earnings ratio of 44.87.

In other Gilead Sciences news, EVP Kevin Young sold 100,000 shares of the stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $81.44, for a total transaction of $8,144,000.00. Following the completion of the sale, the executive vice president now directly owns 216,418 shares of the company’s stock, valued at approximately $17,625,082. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of other firms have also recently commented on GILD. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $80.00 to $95.00 in a research note to investors on Thursday. Separately, analysts at Zacks downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $85.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $95.00 to $132.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Gilead Sciences has an average rating of “Buy” and a consensus price target of $82.54.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.